VY
Voyageur Pharmaceuticals Ltd.
VYYRF · OTC
$0.10 -6.42% (-$0.01)
1M -13.56%
Market Cap $25.6M
P/E Ratio -
Div. Yield -
ROE 371.06%
Bulios Fair Price
$0.07
31.4% downside
Current Price
$0.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VYYRF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 542.34x
P/B 62.72x
P/E N/A
Growth
0 /100
Declining Book val. growth 5.12%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 2,792.45%
Net margin 7,388.13%
Op. margin 8,036.12%
Quality
0 /100
Poor ROIC 846.40%
ROE 371.06%
ROA 108.40%
Debt
67 /100
Low Debt/Equity 0.10x
Current ratio 0.23x
Int. coverage N/A
Stability
24 /100
Unstable Beta 0.29x
EPS volatility 52.68%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VYYRF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Brent Willis
Employees
6
Headquarters
Calgary
Upcoming events
26 OCT
Earnings
Upcoming earnings report